Q1 Earnings Estimate for Immunovant Issued By Zacks Research

Immunovant, Inc. (NASDAQ:IMVT) – Equities research analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Immunovant in a note issued to investors on Tuesday, January 7th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of ($0.82) for the quarter, down from their previous forecast of ($0.79). The consensus estimate for Immunovant’s current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Immunovant’s Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.63) EPS.

A number of other equities analysts have also commented on the stock. Wells Fargo & Company dropped their price target on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Immunovant in a report on Friday, November 8th. Raymond James reiterated an “outperform” rating and issued a $36.00 price objective on shares of Immunovant in a research note on Thursday, October 10th. Wolfe Research downgraded Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. Finally, Oppenheimer lifted their price target on Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $47.22.

Immunovant Trading Down 4.1 %

Shares of Immunovant stock opened at $23.63 on Friday. Immunovant has a 1 year low of $23.62 and a 1 year high of $45.58. The company has a market cap of $3.47 billion, a P/E ratio of -10.64 and a beta of 0.66. The stock has a 50-day moving average price of $27.19 and a 200 day moving average price of $28.61.

Immunovant (NASDAQ:IMVT) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same period last year, the company posted ($0.45) EPS.

Insiders Place Their Bets

In other news, insider William L. Macias sold 3,188 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $28.79, for a total transaction of $91,782.52. Following the completion of the sale, the insider now directly owns 365,144 shares of the company’s stock, valued at $10,512,495.76. The trade was a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark S. Levine sold 4,361 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $29.53, for a total value of $128,780.33. Following the completion of the transaction, the insider now owns 322,878 shares in the company, valued at $9,534,587.34. This represents a 1.33 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 68,037 shares of company stock worth $1,812,464. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IMVT. KBC Group NV lifted its stake in Immunovant by 46.2% during the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after purchasing an additional 612 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Immunovant by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock worth $148,000 after buying an additional 934 shares during the last quarter. Assetmark Inc. boosted its stake in Immunovant by 73.8% in the third quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after buying an additional 1,228 shares in the last quarter. Tyro Capital Management LLC grew its position in Immunovant by 0.6% during the third quarter. Tyro Capital Management LLC now owns 252,149 shares of the company’s stock valued at $7,189,000 after acquiring an additional 1,529 shares during the last quarter. Finally, Quest Partners LLC grew its position in Immunovant by 216.7% during the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock valued at $69,000 after acquiring an additional 1,786 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.